Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Med Res Opin. 2003;19(6):470-2.

The evolving role of telomerase inhibitors in the treatment of cancer.

Author information

  • 1Institute of Cancer Genetics and Pharmacogenomics, Brunel University, and St George's and the Princess Grace Hospitals, London, UK. kefahmokbel@hotmail.com

Abstract

Telomerase is a ribonucleoprotein that maintains telomeres and is essential for cellular immortality and tumour growth. The differential expression of telomerase in cancer cells makes it an attractive therapeutic target. Anti-sense oligonucleotides directed against the RNA template of hTR and small molecules that can interact and stabilise the G-quadruplex represent promising therapeutic strategies. Human trials investigating the potential role of the catalytic subunit hTERT as a universal cancer vaccine have already commenced. Alternative lengthening of telomeres (ALT) and efficacy delay remain important limitations to anti-telomerase therapy.

PMID:
14594517
DOI:
10.1185/030079903125002081
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Taylor & Francis
    Loading ...
    Support Center